For its second fiscal quarter (ending June 30), MacroGenics Inc (NASDAQ: MGNX) has reported a -196% decline in E.P.S. from $0.93 a year ago to $-0.89 in the current quarter. This performance was $-0.30 short of the consensus estimate of $-0.59. E.P.S. were $-2.20 for the latest four quarters through June 30 versus $0.12 for the same period a year ago — a decline of -1933%.
Recent Price Action
On 8/6/24, MacroGenics Inc (NASDAQ: MGNX) stock increased 1.7%, closing at $3.64. However, unusually low trading volume at 52% of normal accompanied the advance. Relative to the market the stock has been extremely weak over the last nine months and has declined -33.5% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to exceed the cost of capital, MGNX is expected to continue to be a major Value Builder.
MacroGenics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. MacroGenics has a poor Appreciation Score of 15 and a very low Power Rating of 1, producing the Lowest Value Trend Rating.
Rating Review
In light of this discouraging new earnings information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment